ストックスクリーナーアプリを入手
4.36
0.69%
0.03
前日終値:
$4.33
開ける：
$4.4
24時間の取引高:
607.58K
Relative Volume:
1.77
時価総額：
$348.92M
収益：
$351.37M
当期純損益:
$-169.52M
株価収益率:
-2.053
EPS:
-2.1237
ネットキャッシュフロー:
$-147.86M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+5.31%
6か月 パフォーマンス:
+39.30%
1年 パフォーマンス:
+35.83%
1日の値動き範囲:
$4.23
$4.46
1週間の範囲:
$4.225
$4.585
52週間の値動き範囲:
$2.78
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Compare AVIR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
4.36 | 348.92M | 351.37M | -169.52M | -147.86M | -2.1237 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-13 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-10-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 開始されました | Evercore ISI | Outperform |
| 2020-11-24 | 開始されました | JP Morgan | Overweight |
| 2020-11-24 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-24 | 開始されました | William Blair | Outperform |
すべてを表示
Atea Pharmaceuticals Inc (AVIR) 最新ニュース
Atea Pharmaceuticals Inc (AVIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Atea Pharmaceuticals (AVIR) AGM 2026 Summary - Quartr
Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atea Pharmaceuticals Inc (AVIR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atea Pharmaceuticals Inc (AVIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atea Pharmaceuticals Inc (AVIR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atea Pharmaceuticals Inc (AVIR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Atea Pharmaceuticals Inc (AVIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Atea Pharmaceuticals Inc (AVIR) Institutional Confidence - TradingKey
Atea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16 - MSN
Atea Pharmaceuticals Inc (AVIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Are medical stocks lagging Atea Pharmaceuticals (AVIR) this year? - MSN
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
Atea Pharmaceuticals (AVIR) Rallies 1.65% as Shares Test Key Resistance Near $4.54Scalping Stock Signals - newsline.com
Atea Pharmaceuticals (AVIR) Declines 3.85% as Shares Approach Key Support LevelPCR Mean Reversion - newsline.com
AVIR Stock Chart | ATEA PHARMACEUTICALS INC (NASDAQ:AVIR) - ChartMill
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea PharmaceuticalsI'm Optimistic Ahead Of Critical HPV Catalyst (NASDAQ:AVIR) - Seeking Alpha
Atea Pharmaceuticals Q1 earnings call highlights - MSN
Atea Pharmaceuticals Q1 2026 Earnings: Narrower Loss Beats Expectations; Stock Edges HigherFiscal Year Earnings - The Legal Advocate
Atea Pharmaceuticals Rises After Hepatitis C Data; 2026 Readouts Eyed - Bez Kabli
Atea presents hepatitis C drug interaction data at EASL - Investing.com UK
Atea Pharmaceuticals Presents New Drug-Drug Interaction - GlobeNewswire
Atea Pharmaceuticals (AVIR) Gains 4.25% as Biotech Sentiment Lifts the StockValue Factor - Newser
Spotlight On Atea Pharmaceuticals And 2 Other Prominent Penny Stocks - Yahoo Finance
Atea Pharmaceuticals (AVIR) Edges Higher Amid Renewed Investor InterestBuffered ETF - Newser
Atea Pharmaceuticals (AVIR) Gains 4.25% as Stock Tests Key Resistance LevelActive ETF Flow - The Legal Advocate
Atea Pharmaceuticals (AVIR) Shows Modest Uptick, Holding Above Key SupportCommunity Pattern Alerts - Newser
Atea Pharmaceuticals director Polly Murphy buys $25,446 in stock By Investing.com - Investing.com Canada
Atea Pharmaceuticals director Polly Murphy buys $25,446 in stock - Investing.com
Atea Pharmaceuticals (AVIR) director buys 6,100 shares of stock - Stock Titan
Atea (AVIR) director adds 6,100 shares in open-market purchase - Stock Titan
Atea Pharma (AVIR) Stock: Up +1.69%, Key Resistance at $4.42 2026-05-19Community Exit Signals - Newser
Here's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Yahoo Finance
Down 25% in 4 weeks, here's why Atea Pharmaceuticals (AVIR) looks ripe for a turnaround - MSN
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss By Investing.com - Investing.com South Africa
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss - Investing.com Nigeria
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Cuts Target Price to $4.1 - Moomoo
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround - Yahoo Finance
Atea Pharmaceuticals (AVIR.US) will release its earnings report after the market closes on May 12. - Moomoo
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline - Sahm
We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully - Moomoo
Atea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call - TipRanks
Atea Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2026 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals Announces Three Accepted Abstracts for Presentation at EASL Congress 2026 - Quiver Quantitative
Atea Pharmaceuticals to Present Three Abstracts at EASL - GlobeNewswire
Atea Pharmaceuticals Inc (AVIR) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):